Open AccessEvaluation of Ceftobiprole Activity against a Variety of Gram-Negative Pathogens, Including Escherichia coli, Haemophilus influenzae (β-Lactamase Positive and β-Lactamase Negative), and Klebsiella pneumoniae, in a Rabbit Meningitis Model
Author(s) -
Andreas Stucki,
Marianne Cottagnoud,
Fernando Acosta,
Ueli Egerman,
J.M. Läuffer,
Philippe Cottagnoud
Publication year - 2012
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01537-10
Subject(s) - microbiology and biotechnology , haemophilus influenzae , klebsiella pneumoniae , escherichia coli , cephalosporin , biology , staphylococcus aureus , antibiotics , bacteria , biochemistry , genetics , gene
Ceftobiprole medocaril, a new cephalosporin, is highly active against a broad spectrum of Gram-positive and Gram-negative clinical pathogens, including methicillin-resistantStaphylococcus aureus (MRSA) and penicillin-resistant pneumococci. In this study, we tested ceftobiprole against various Gram-negative pathogens in a rabbit meningitis model and determined its penetration into the cerebrospinal fluid (CSF). In this animal model, ceftobiprole produced an antibacterial activity similar to that of cefepime against anEscherichia coli strain, aKlebsiella pneumoniae strain, and a β-lactamase-negativeHaemophilus influenzae strain. Against a β-lactamase-positiveH. influenzae strain, ceftobiprole was significantly superior. The penetration of ceftobiprole through inflamed meninges reached about 16% of serum levels compared to about 2% of serum levels through uninflamed meninges.